PMID- 23142720
OWN - NLM
STAT- MEDLINE
DCOM- 20130722
LR  - 20131121
IS  - 1872-7972 (Electronic)
IS  - 0304-3940 (Linking)
VI  - 531
IP  - 2
DP  - 2012 Dec 7
TI  - Memantine attenuates 3,4-methylenedioxymethamphetamine-induced hyperthermia in 
      rats.
PG  - 198-203
LID - S0304-3940(12)01441-3 [pii]
LID - 10.1016/j.neulet.2012.10.059 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) is an illegal drug that can induce 
      life-threatening hyperthermia. No effective pharmacological treatment for 
      MDMA-induced hyperthermia has yet been established. We investigated the effects 
      of memantine, a non-competitive N-methyl-D-aspartate (NMDA)-type glutamate 
      receptor antagonist and an alpha-7 nicotinic acetylcholine receptor (nAChR) 
      antagonist, on MDMA-induced hyperthermia in rats. Treatment of animals with 
      memantine (10 or 20 mg/kg) either before or after MDMA (10 mg/kg) administration 
      significantly decreased the peak body temperature. Results from our microdialysis 
      study indicated that pretreatment with memantine (20 mg/kg) before MDMA 
      administration had no effect on the MDMA-induced increase in serotonin (5-HT) and 
      dopamine (DA) levels in the anterior hypothalamus. MDMA-induced hyperthermia was 
      significantly suppressed by pretreatment with the non-competitive NMDA receptor 
      antagonist MK-801 (0.5 mg/kg) and the competitive NMDA antagonist CGS 19755 (5 
      mg/kg), but not by the selective alpha-7 nAChR antagonist methyllycaconitine (6 or 10 
      mg/kg). These results indicate that the inhibitory effect of memantine on 
      MDMA-induced hyperthermia may be due to its activity as an NMDA receptor 
      antagonist and not as a result of a direct effect on the 5-HT or DA systems. The 
      present study suggests that moderate doses of memantine may be useful for the 
      treatment of MDMA-induced hyperthermia in humans.
CI  - Copyright (c) 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Nisijima, Koichi
AU  - Nisijima K
AD  - Department of Psychiatry, Jichi Medical University, Tochigi, Japan. 
      midorin@jichi.ac.jp
FAU - Kuboshima, Kyoko
AU  - Kuboshima K
FAU - Shioda, Katsutoshi
AU  - Shioda K
FAU - Yoshino, Tatuki
AU  - Yoshino T
FAU - Iwamura, Tatsunori
AU  - Iwamura T
FAU - Kato, Satoshi
AU  - Kato S
LA  - eng
PT  - Journal Article
DEP - 20121106
PL  - Ireland
TA  - Neurosci Lett
JT  - Neuroscience letters
JID - 7600130
RN  - 0 (Dopamine Agents)
RN  - 0 (Hallucinogens)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - VTD58H1Z2X (Dopamine)
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Animals
MH  - Brain Chemistry/drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Dopamine/analysis/metabolism
MH  - Dopamine Agents/*pharmacology
MH  - Fever/chemically induced/*drug therapy
MH  - Hallucinogens/*toxicity
MH  - Hypothalamus/drug effects/metabolism
MH  - Male
MH  - Memantine/*pharmacology
MH  - Microdialysis
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*toxicity
MH  - Rats
MH  - Rats, Wistar
MH  - Serotonin/analysis/metabolism
EDAT- 2012/11/13 06:00
MHDA- 2013/07/23 06:00
CRDT- 2012/11/13 06:00
PHST- 2012/09/07 00:00 [received]
PHST- 2012/10/23 00:00 [revised]
PHST- 2012/10/25 00:00 [accepted]
PHST- 2012/11/13 06:00 [entrez]
PHST- 2012/11/13 06:00 [pubmed]
PHST- 2013/07/23 06:00 [medline]
AID - S0304-3940(12)01441-3 [pii]
AID - 10.1016/j.neulet.2012.10.059 [doi]
PST - ppublish
SO  - Neurosci Lett. 2012 Dec 7;531(2):198-203. doi: 10.1016/j.neulet.2012.10.059. Epub 
      2012 Nov 6.